Arecor Therapeutics annual ebitda
2022
2023
2024
2025
Arecor Therapeutics EBITDA Growth & History (AREC)
Arecor Therapeutics's calculated EBITDA was £1.2M for fiscal 2025.
View full Arecor Therapeutics company overviewArecor Therapeutics annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | £1.2M | £5.9M | — |
| 2024 | 2024-12-31 | −£4.7M | £3.7M | — |
| 2023 | 2023-12-31 | −£8.4M | £1.7M | — |
| 2022 | 2022-12-31 | −£10.1M | — | — |
Arecor Therapeutics ebitda trends
Between the periods ended 2022-12-31 and 2025-12-31, Arecor Therapeutics's ebitda increased from −£10.1M to £1.2M, a change of £11.3M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Arecor Therapeutics source filings ↗Community posts
Arecor conditionally raises £5 million to extend insulin-development funding
Arecor Therapeutics ($AREC-LSE) has conditionally placed approximately 7.35 million new shares at 68 pence each, raising about £5 million before expenses. The financing follows an accelerated bookbuild and is separate from a planned retail ...
